Great Basin this week named six distributors in Europe and one in New Zealand for its recently commercialized molecular diagnostic test for Clostridium difficile.
Salt Lake City-based Great Basin's distributors include: AlphaScience in Germany; Lab-Tech in Denmark, Finland, Iceland, Norway, and Sweden; Buhlmann Labs in Austria, France, Lichtenstein, and Switzerland; Emelca Biosciences in Belgium, Netherlands, and Luxembourg; and Pro-Lab Diagnostics in the UK.
The company also said that it has partnered with NGAIO Diagnostics to distribute its products in New Zealand.
In addition, Great Basin said that it recently hired Miquel Vernet to represent the company and maintain its distribution partnerships in Europe, as part of a wave of new hires designed to support the company's worldwide commercialization efforts (see People in the News, this issue).
Great Basin's C. difficile test is contained on an integrated disposable cartridge containing all necessary reagents, and runs on the company's yet-to-be-named automated testing platform that features chip-based detection using thin-film biosensor technology, as well as dedicated analysis software. The platform can multiplex up to 64 distinct targets in a single assay; provides results in less than an hour, depending on the target; and features on-demand testing with no test batching.
The company received CE-IVD product marking for its C. difficile assay earlier this year; and in May, it received US Food and Drug Administration 510(k) clearance for the test (PCR Insider, 5/3/2012). Great Basin is also working on an assay panel to identify major pathogenic and methicillin-resistant strains of Staphylococcus in blood culture; and a panel to detect Candida infections in blood (PCR Insider, 3/8/2012).